ACTUATE THERAPEUTICS INC
ACTUNASDAQ🏆 #3518 by market capUS Equity
$584.27▼ $11.98 (−2.05%)
Simulated price1h—
24h▼ 2.0%
7d—
14d—
30d—
1y—
🏦Market Cap
$24M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
53
Weak
No chart data available for ACTU.
Trading Snapshot
- Day Range
- $577.92 – $588.89
- 52-Week Range
- $1.00 – $9.22
- Volume
- $5.46B
- Avg Volume
- $5.03B
- Shares Outstanding
- 23.9M
- Next Earnings
- Sep 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.99
- Dividend Yield
- —
Why Investors Own ACTU
- ✓High-growth profile — revenue up +13.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$4M▲ +18.6% YoY
Gross Margin (TTM)
45.1%▲ +1.4% YoY
Operating Income (TTM)
$1M▲ +18.6% YoY
Free Cash Flow (TTM)
$1M▲ +18.6% YoY
About ACTUATE THERAPEUTICS INC
A company profile for ACTUATE THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
53/100
Analyst Price Target
ⓘAverage Target
$602.94
▲ +3.2% Upside
High Target$703.03
Low Target$500.16
Based on 11 analysts
Latest News & Updates
🚀
CNBC·2h ago
ACTUATE THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift ACTU price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
ACTUATE THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.